Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: A comparison of two populations from different geographical regions

European Journal of Histochemistry

Volumn 50, Issue 3, 2006, Pages 191-198

  Sirigu, Paola ^a,c   Piras, F ^a   Minerba, L ^a   Murtas, D ^a   Maxia, C ^a   Colombari, R ^b   Corbu, A ^a   Perra, M T ^a   Ugalde, J ^c  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b City Hospital   (Italy)

^c Instituto del Cancer de Solca   (Ecuador)

Author keywords

Biological markers; Cutaneous melanoma; p16; p53; Prognosis

Indexed keywords

CYTOPLASM PROTEIN; PROTEIN P16; PROTEIN P53; PROTEIN P16INK4A;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GEOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MELANOMA; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; ANIMAL; ECUADOR; ETHNIC AND RACIAL GROUPS; ITALY; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ECUADOR; FEMALE; HUMANS; ITALY; MALE; MELANOMA; MIDDLE AGED; POPULATION GROUPS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39049194005     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004; 164:193-203.
2. Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv 1994; 19-20:219-40.
3. Bachmann IM, Straume O, Akslen LA. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol 2004; 25:1559-65.
4. Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, Murad TM, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982; 196(6):677-84.
5. Balch CM: Cutaneous Melanoma. In: AJCC Cancer Staging Manual (6th edition). Edited by FL Greene, DL Page, ID Fleming et al. Springer Verlag, New York, 2002, pp. 209-17.
6. Bulliard JL, Cox B, Elwood JM. Comparison of the site distribution of melanoma in New Zealand and Canada. Int J Cancer 1997; 72:231-5.
7. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705-27.
8. Clark WH Jr, Elder DE, Guerry D 4th, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-904.
9. Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988-93. Cancer Causes Control 1997; 8:246-52.
10. Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations - US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol 2005; 141:477-81.
11. Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther 2005; 18:369-85.
12. Evangelou K, Bramis J, Peros I, Zacharatos P, Dasiou-Plakida D, Kalogeropoulos N, et al. Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas. Biotech Histochem 2004; 79:5-10.
13. Ghiorzo P, Mantelli M, Gargiulo S, Gramigni C, Pastorino L, Banelli B et al. Inverse correlation between p16INK4A expression and NF-kappaB activation in melanoma progression. Hum Pathol 2004; 35:1029-37.
14. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003; 21:217-28.
15. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 1999; 85:375-82.
16. Johnson DS, Yamane S, Morita S, Yonehara C, Wong JH. Malignant melanoma in non-Caucasians: experience from Hawaii. Surg Clin North Am 2003; 83:275-82.
17. Hussein MR, Haemel AK, Wood GS. p53-related pathways and the molecular pathogenesis of melanoma. Eur J Cancer Prev 2003; 12:93-100.
18. Matsumura Y, Ananthaswamy HN. Molecular mechanisms of photocarcinogenesis. Front Biosci 2002; 7:765-83.
19. Mihic-Probst D, Mnich CD, Oberholzer PA, Seifert B, Sasse B, Moch H et al. p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer 2006; 118:2262-8.
20. Nilsson K, Landberg G. Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells. Int J Cancer 2006; 118:1120-5.
21. (NCR), Solca Quito, Cancer en regiones de Ecuador. Cancer in Ecuadorian Regions 1995-2000; 1-286.
22. Ohtani N, Yamakoshi K, Takahashi A, Hara E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 2004; 51:146-53.
23. Pavey SJ, Cummings MC, Whiteman DC, Castellano M, Walsh MD, Gabrielli BG, et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 2002; 12:539-47.
24. Soufir N, Basset-Seguin N. The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis. Bull Cancer 2001; 88:1061-7.
25. Sparrow LE, Eldon MJ, English DR, Heenan PJ. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20:255-61.
26. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000; 6:1845-53.
27. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997; 74:255-9.
28. Tsai T, Vu C, Henson DE. Cutaneous, ocular and visceral melanoma in African Americans and Caucasians. Melanoma Res 2005; 15:213-7.
29. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003; 22:3042-52.
30. Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, et al. Ultraviolet A and melanoma: a review. J. Am Acad Dermatol 2001; 44:837-46.
31. Weinstock MA. Progress and prospects on melanoma: the way forward for early detection and reduced mortality. Clin Cancer Res 2006; 12(7 Pt 2):2297s-2300s.
32. Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998; 77:843-8.